UCB (EBR:UCB) UCB Media Room: Disposal of own shares
Directive transparence : information réglementée Communiqué sur comptes, résultats, chiffres d’affaires
07/03/2022 20:04
https://mb.cision.com/Public/18595/3520169/a723bdd01a9874de_800x800ar.png
** Disposal of own shares
------------------------------------------------------------
Brussels (Belgium), 7 March 2022 =E2=80=93 20:00 (CET) =E2=80=93 Regulated =
information=C2=A0
In accordance with article 8:6 of the Royal Decree executing the Belgian Co=
de of Companies and Associations, UCB announces that, following exercises o=
f stock options by members of its personnel, it has disposed of UCB shares =
OTC in view of deliveries of these shares to the relevant members of the pe=
rsonnel, within the framework of the Long-Term Incentive Program of the UCB=
Group, as follows:
https://mb.cision.com/Public/18595/3520169/8cb7ed31bd30720c_800x800ar.png
https://mb.cision.com/Public/18595/3520169/bedfdf8a9bc71e71_800x800ar.png
In addition to these exercises, on 2 March 2022, in accordance with the ves=
ting rules under its 2020 and 2021 LTI plans, UCB SA/NV has delivered for f=
ree a total of 328 UCB shares OTC to 2 members of the personnel of the Comp=
any and its subsidiaries. The highest independent bid price on Euronext Bru=
ssels on 2 March 2022 was =E2=82=AC 99,82.
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://www.ucb.com/stories-media/Press-Releases) .
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte=C2=A0
T +32 2 559 94 14
antje.witte@ucb.com
Corporate Communications
Laurent Schots=C2=A0
T+32 2 559 92 64
laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 600 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.8 bi=
llion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news
=C2=A0
GenericFile
220307 - Vervreemding van eigen aandelen NL (https://mb.cision.com/Public/1=
8595/3520169/a6f9a6670e7ff084.pdf) GenericFile
220307 - Disposals of own shares ENG (https://mb.cision.com/Public/18595/35=
20169/bd6ba5b71f6f77d2.pdf) GenericFile
220307 - Ali=C3=A9nation d actions propres FR (https://mb.cision.com/Public=
/18595/3520169/bdcd8b4f99a3e52d.pdf) Image
Chart 1 March 7 2022 (https://mb.cision.com/Public/18595/3520169/8cb7ed31bd=
30720c_org.png) Image
Chart 2 March 7 2022 (https://mb.cision.com/Public/18595/3520169/bedfdf8a9b=
c71e71_org.png)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x98483x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01